Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Methylprednisolone acetate
Drug ID BADD_D01434
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code Not Available
DrugBank ID Not Available
KEGG ID D00979
MeSH ID D000077555
PubChem ID 5877
TTD Drug ID Not Available
NDC Product Code 0009-0026; 10695-041; 38779-0144; 46439-8767; 82298-117; 0009-0274; 50090-6024; 60219-1574; 0009-0306; 68788-8082; 76420-262; 0781-3516; 51552-0958; 0009-3073; 76420-260; 25021-821; 0009-0280; 50090-0436; 49452-4688; 71052-161; 25021-820; 70121-1552; 76420-081; 60722-1007; 0009-3475; 55150-313; 63187-474; 70121-1573; 70121-1574; 52128-148; 42023-239; 42023-240; 55150-314; 51927-0000; 63275-9942; 65089-0016; 50090-0556; 51662-1429; 22552-0023; 50090-5894; 60219-1573
UNII 43502P7F0P
Synonyms Methylprednisolone Acetate | Methylprednisolone-21-acetate | Methylprednisolone 21 acetate | Acetyl-Methylprednisolone | Acetyl Methylprednisolone | Depo-Medrone | Depo Medrone | Depo-Medrol | Depo Medrol | Methylprednisolone Acetate, (11beta,16beta)-isomer | Methylprednisolone Acetate, (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C24H32O6
CAS Registry Number 53-36-1
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Increased insulin requirement05.06.01.006; 14.06.01.006--Not Available
Infection11.01.08.002--Not Available
Infection susceptibility increased11.01.08.004; 10.02.01.046--Not Available
Injection site abscess12.07.03.021; 11.01.08.023; 08.02.03.021--Not Available
Injection site infection12.07.03.008; 11.01.08.005; 08.02.03.019--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Intestinal perforation07.04.06.002--Not Available
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Large intestine perforation07.04.06.005; 12.02.03.005--
Leukocytosis01.02.01.002--
Leukoderma23.05.02.001--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Meningitis17.06.03.001; 11.01.03.001--
Menstruation irregular21.01.01.005; 05.05.01.008--
Metabolic acidosis14.01.01.003--Not Available
Monoplegia17.01.04.003--Not Available
Mood swings19.04.03.001--Not Available
Muscle atrophy17.05.03.004; 15.05.03.003--Not Available
Muscle disorder15.05.03.014--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial rupture12.01.11.002; 02.04.02.002--Not Available
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages